Literature DB >> 9488224

Plasma atrial natriuretic peptide and natriuretic peptide receptor gene expression in adipose tissue of normotensive and hypertensive obese patients.

P Dessì-Fulgheri1, R Sarzani, P Tamburrini, A Moraca, E Espinosa, G Cola, L Giantomassi, A Rappelli.   

Abstract

OBJECTIVE: Human and rat adipose tissue contain very high levels of natriuretic peptides clearance receptor messenger (m)RNA, and fasting inhibits its gene expression in adipose tissue. In this study we evaluated plasma atrial natriuretic peptide (ANP) and gene expression of biologically active type A natriuretic peptide receptor (NPr-A) and clearance natriuretic peptide receptor (NPr-C) in adipose tissue of obese hypertensive and obese normotensive patients. DESIGN AND METHODS: We studied 27 untreated obese hypertensives, 26 obese normotensives (body mass index > or = 30 kg/m2), 24 non-obese essential hypertensives and 23 lean healthy subjects (body mass index < or = 25 kg/m2). Blood samples were withdrawn for ANP, plasma renin activity and aldosterone radioimmunoassays. Subcutaneous peri-umbilical adipose tissue samples were obtained, by needle aspiration, in 13 obese hypertensives and in 12 obese normotensives and used for RNA extraction. Then, complementary synthesis and semiquantitative polymerase chain reaction (PCR) with primers complementary to sequences of different exons of the genes encoding for NPr-A, NPr-C and beta-actin, were performed. 32P-labeled PCR products were separated by electrophoresis, blotted onto nylon membranes, and the exposed autoradiographic films were analysed by densitometry. NPr signals were normalized by the beta-actin expression level.
RESULTS: Plasma ANP was lower in obese hypertensives than in obese normotensives (37.5+/-7 versus 43.2+/-6 pg/ml, P< 0.05), but was higher in non-obese hypertensives than in non-obese normotensives. In contrast, plasma renin activity and aldosterone were higher in the obese hypertensives. Although NPr-A and NPr-C expression were not statistically different between the two obese groups, the NPr-A: NPr-C mRNA ratios were significantly lower in obese hypertensives (P < 0.03).
CONCLUSIONS: Our data suggest that in obese hypertensives compared to obese normotensives, the lower NPr-A: NPr-C ratio might determine decreased biological activity and/or an increased clearance of natriuretic peptide in adipose tissue, suggesting that the natriuretic peptide and its receptor system may be important in obesity-related hypertension where ANP levels are lower.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9488224     DOI: 10.1097/00004872-199715120-00074

Source DB:  PubMed          Journal:  J Hypertens        ISSN: 0263-6352            Impact factor:   4.844


  46 in total

Review 1.  Obesity and hypertension.

Authors:  E Faloia; G Giacchetti; F Mantero
Journal:  J Endocrinol Invest       Date:  2000-01       Impact factor: 4.256

Review 2.  New developments in mechanisms of obesity-induced hypertension: role of adipose tissue.

Authors:  A M Sharma; S Engeli; T Pischon
Journal:  Curr Hypertens Rep       Date:  2001-04       Impact factor: 5.369

3.  Cardiac natriuretic peptides act via p38 MAPK to induce the brown fat thermogenic program in mouse and human adipocytes.

Authors:  Marica Bordicchia; Dianxin Liu; Ez-Zoubir Amri; Gerard Ailhaud; Paolo Dessì-Fulgheri; Chaoying Zhang; Nobuyuki Takahashi; Riccardo Sarzani; Sheila Collins
Journal:  J Clin Invest       Date:  2012-02-06       Impact factor: 14.808

Review 4.  A heart-adipose tissue connection in the regulation of energy metabolism.

Authors:  Sheila Collins
Journal:  Nat Rev Endocrinol       Date:  2013-12-03       Impact factor: 43.330

5.  Sex-specific associations of obesity and N-terminal pro-B-type natriuretic peptide levels in the general population.

Authors:  Navin Suthahar; Wouter C Meijers; Jennifer E Ho; Ron T Gansevoort; Adriaan A Voors; Peter van der Meer; Stephan J L Bakker; Stephane Heymans; Vanessa van Empel; Blanche Schroen; Pim van der Harst; Dirk J van Veldhuisen; Rudolf A de Boer
Journal:  Eur J Heart Fail       Date:  2018-06-01       Impact factor: 15.534

6.  Increasing aminoterminal-pro-B-type natriuretic peptide precedes the development of arterial hypertension: the multiethnic study of atherosclerosis.

Authors:  Otto A Sanchez; David R Jacobs; Hossein Bahrami; Carmen A Peralta; Lori B Daniels; João A Lima; Alan Maisel; Daniel A Duprez
Journal:  J Hypertens       Date:  2015-05       Impact factor: 4.844

7.  Excessive Adiposity and Metabolic Dysfunction Relate to Reduced Natriuretic Peptide During RAAS Activation in HIV.

Authors:  Caitlin A Murphy; Kathleen V Fitch; Meghan Feldpausch; Patrick Maehler; Kimberly Wong; Martin Torriani; Gail K Adler; Steven K Grinspoon; Suman Srinivasa
Journal:  J Clin Endocrinol Metab       Date:  2018-04-01       Impact factor: 5.958

Review 8.  The impacts of obesity on the cardiovascular and renal systems: cascade of events and therapeutic approaches.

Authors:  Zohreh Soltani; Vaughn Washco; Stephen Morse; Efrain Reisin
Journal:  Curr Hypertens Rep       Date:  2015-02       Impact factor: 5.369

9.  Progressive cardiac hypertrophy and dysfunction in atrial natriuretic peptide receptor (GC-A) deficient mice.

Authors:  M Kuhn; R Holtwick; H A Baba; J C Perriard; W Schmitz; E Ehler
Journal:  Heart       Date:  2002-04       Impact factor: 5.994

Review 10.  Central role of guanylyl cyclase in natriuretic peptide signaling in hypertension and metabolic syndrome.

Authors:  G Martel; P Hamet; Johanne Tremblay
Journal:  Mol Cell Biochem       Date:  2009-11-25       Impact factor: 3.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.